The Motley Fool on MSN13d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
Jim Cramer on Vertex (VRTX): “A Revolutionary Anti-Pain Drug”
We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...
BioSpace4d
Purdue Files for Bankruptcy Anew to Support $7.4B+ Opioid Settlement
The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...
MedCity News1mon
Vertex Pharmaceuticals
Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a ...
BioPharma Dive7d
Latigo raises $150M to get non-opioid pain drugs through key tests
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
GEN - Genetic Engineering and Biotechnology News4d
From Tools to Trials: Editing Therapy Companies Pivot to Development
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Nasdaq13d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...